SCHEMBL17100766

SCHEMBL17100766

Fc1ccccc1-c1noc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.63
HSD17B10 Q99714 2/20 0.63
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
CYP1A2 P05177 2/20 0.53
CYP3A4 P08684 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
MAPK1 P28482 2/20 0.53
USP2 O75604 1/20 0.53
HTR1A P08908 1/20 0.53
ADRA2A P08913 1/20 0.53
DRD2 P14416 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53
NFKB1 P19838 1/20 0.53
SLC6A2 P23975 1/20 0.53
SLC6A4 P31645 1/20 0.53
ADRA1A P35348 1/20 0.53
DRD3 P35462 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17100584 0.85 KDM4E (0.58) KDM4EHSD17B10MEN1KMT2ACYP1A2
SCHEMBL17100611 0.84 MAPK1 (0.57) KDM4EHSD17B10MEN1KMT2ACYP2D6
SCHEMBL17100869 0.81 LMNA (0.56) KDM4EHSD17B10MEN1KMT2ACYP1A2
SCHEMBL17100737 0.80 ALDH1A1 (0.55) KDM4EHSD17B10MEN1KMT2ACYP1A2
SCHEMBL11518394 0.79 MEN1 (0.58) KDM4EHSD17B10MEN1KMT2ACYP1A2
SCHEMBL17100602 0.78 CYP2D6 (0.56) KDM4EHSD17B10MEN1KMT2ACYP1A2
SCHEMBL17100770 0.77 POLB (0.64) KDM4EHSD17B10MEN1KMT2ACYP1A2
SCHEMBL17100594 0.77 MAPT (0.58) KDM4EHSD17B10MEN1KMT2ACYP1A2
SCHEMBL17100837 0.77 MAPT (0.56) HSD17B10MEN1KMT2ACYP1A2CYP3A4
SCHEMBL17100642 0.75 MEN1 (0.52) KDM4EHSD17B10MEN1KMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US claimed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US claimed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP claimed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO claimed
US-20200140400-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2020-05-07 US disclosed
US-10562869-B2 Oxadiazole compounds REMYND NV (BE) 2020-02-18 US disclosed
US-20170073319-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2017-03-16 US disclosed
EP-3119774-A1 OXADIAZOLE COMPOUNDS reMynd NV (BE) 2017-01-25 EP disclosed
WO-2015140130-A1 OXADIAZOLE COMPOUNDS REMYND NV (BE) 2015-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562869-B2 Oxadiazole compounds OXA1L, PSEN1, MAPT KDM4E 4760/4885HSD17B10 790/4885MEN1 2665/4885
US-20200140400-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT KDM4E 4743/4885HSD17B10 902/4885MEN1 2837/4885
US-20170073319-A1 OXADIAZOLE COMPOUNDS OXA1L, PSEN1, MAPT KDM4E 4760/4885HSD17B10 790/4885MEN1 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.